Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 156 Jul 27 – Oct 24, 2026
- Disclosed funding
- $5.9B 121 disclosed amounts
- Median round
- $24M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| NB Novadip BiosciencesCompany profile A clinical-stage biotechnology company developing regenerative cell therapies and grafts to repair bone and other damaged tissues, including a pivotal-stage treatment for a rare pediatric bone disorder. A clinical-stage biotechnology company developing regenerative cell therapies and grafts to repair bone and other damaged tissues, including a pivotal-stage treatment for a rare pediatric bone disorder. | €10.4M | Convertible financingUndisclosed | Biotech | Belgium | Investors | |
| R RobigoCompany profile Robigo engineers biological crop-protection solutions that use targeted microbes to control plant pathogens while preserving beneficial organisms. Robigo engineers biological crop-protection solutions that use targeted microbes to control plant pathogens while preserving beneficial organisms. | Undisclosed | Series A | Biotech, Agritech | United States | Investors | |
| TT Tempo TherapeuticsCompany profile A regenerative-medicine company developing injectable microporous scaffolds that help the body rebuild tissue at damaged sites. A regenerative-medicine company developing injectable microporous scaffolds that help the body rebuild tissue at damaged sites. | $14.5M | FundingUndisclosed | Biotech | United States | Investors | |
| ER Eterna RegenerativesCompany profile Eterna Regeneratives develops keratin-based biomaterials that guide mineral growth to repair enamel and, in a separate application, support bone regeneration. Its research-led platform is moving from proof of concept toward dental and orthopaedic products. Eterna Regeneratives develops keratin-based biomaterials that guide mineral growth to repair enamel and, in a separate application, support bone regeneration. Its research-led platform is moving from proof of concept toward dental and orthopaedic products. | $4M | Seed | Biotech, Healthtech | United Kingdom | Investors | |
| P PolyphronCompany profile An AI-guided tissue-engineering platform that grows human micro-tissues and models their responses to support drug research and development. An AI-guided tissue-engineering platform that grows human micro-tissues and models their responses to support drug research and development. | $20M | Seed | Biotech | United States | Investors | |
| BP Big Picture BioCompany profile Big Picture Bio builds a cancer research model that predicts which drug combinations may work together, helping biopharma teams prioritize therapies and experiments. Big Picture Bio builds a cancer research model that predicts which drug combinations may work together, helping biopharma teams prioritize therapies and experiments. | £2.2M | Pre-seed and Innovate UK grant packagePre-seed | Biotech | United Kingdom | Investors | |
| AL Anew LabsCompany profile An AI drug-discovery company that combines molecular models, experimental biology and a drug pipeline to identify and develop new medicines. An AI drug-discovery company that combines molecular models, experimental biology and a drug pipeline to identify and develop new medicines. | $290M | FundingUndisclosed | Biotech | China | Investors | |
| C ChemifyCompany profile Chemify turns digital chemistry programs into real molecules through software, robotics and AI. Pharmaceutical, biotechnology and materials R&D teams can use its Chemputation platform and automated Chemifarm to design, synthesize and test compounds. Chemify turns digital chemistry programs into real molecules through software, robotics and AI. Pharmaceutical, biotechnology and materials R&D teams can use its Chemputation platform and automated Chemifarm to design, synthesize and test compounds. | £22M | £22 million grant packageUndisclosed | Biotech, Industrial tech | United Kingdom | Investors | |
| M MithrlCompany profile Mithrl builds a scientific decision engine for biopharma and research teams. Its biomedical world model combines validated biological knowledge with each organization’s data, then uses AI agents and workflows to help scientists analyze experiments, assess hypotheses and accelerate drug-discovery decisions; the company is preparing its next-generation platform for broader deployment. Mithrl builds a scientific decision engine for biopharma and research teams. Its biomedical world model combines validated biological knowledge with each organization’s data, then uses AI agents and workflows to help scientists analyze experiments, assess hypotheses and accelerate drug-discovery decisions; the company is preparing its next-generation platform for broader deployment. | $20M | Series A | Biotech, AI | United States | Investors | |
| ST Sling Therapeutics, Inc.Company profile A clinical-stage biotechnology company developing an oral drug candidate for thyroid eye disease. A clinical-stage biotechnology company developing an oral drug candidate for thyroid eye disease. | $123M | Series CSeries C+ | Biotech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jul 27, 2026
- 1Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
10rounds0led - 2RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
9rounds3led - 3Y Combinator (YC)
Molagri, Sensible Biotechnologies, WonderTx
6rounds0led - 4Catalio Capital Management
BigHat Biosciences, Basecamp Research, Enveda
6rounds2led - 5Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
5rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.